Pharmacyte Biotech Inc (OTCMKTS:PMCB), a leading biotech company known for conducting high-tech pancreatic cancer trials has announced major milestones right before the phase 2b clinical trial in pancreatic cancer begins.
The company has developed a treatment for pancreatic cancer, and this trial is likely to test the efficiency of this trial. As per the reports, the treatment comprises of low doses of ifosfamide, better known as the chemotherapy drug and microcapsules with genetically modified live cells.
Major Milestones To Take Place In Coming Weeks
Establishment of IND Team: Pharmacyte will set up an IND team for the fulfillment of all the review formalities before submitting it to authorities. Some of the key resources to be included in this team make room for — a Project Manager, a Statistician, a Medical Officer, a Chemistry and a Pharmacologist. Apart from them, the team will also have a Manufacturing and Controls Expert, a Pharmakineticist, an Interventional Radiologist, a Toxicologist, a Regulatory Affairs person and a Radiologist.
Other milestones to be achieved before the trial can begin are — finalization of trial design, clinical protocol, Chemistry, Manufacturing and Controls Information, clinical trial study website, etc. Pharmacyte hopes to finish all these milestones on time to ensure a smooth initiation of trials.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has announced an update concerning its listing on NASDAQ marketplace. Stellar Biotechnologies has scheduled a shareholder meeting on October 29, 2015, during which it will discuss a few important corporate governance requirements. The board of directors of Stellar has urged shareholders to approve these changes to carry out the listing procedure in a hassle-free way.
USANA Health Sciences, Inc. (NYSE:USNA)‘s continuous hard work has paid off as the company has secured a place among top 50 companies in Utah state. The list focuses on top-notch companies that drive growth faster than other companies. It’s the 8th occasion when USANA has made it to the list.
